Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 19:4:213.
doi: 10.3389/fonc.2014.00213. eCollection 2014.

Maintenance therapies for non-small cell lung cancer

Normand Blais  1 , Elie Kassouf  1
Affiliations
Review

Maintenance therapies for non-small cell lung cancer

Normand Blais et al. Front Oncol. .

Abstract

Treatment of lung cancer had evolved during the last decade with the introduction of new chemotherapeutic regimens and targeted therapies. However, the maximum benefit reached after first-line therapy is limited by the cumulative toxicity of platinum drugs and the subsequent deterioration in performance status in a high percentage of patients who end up receiving not more than one line of treatment. Maintenance therapy had been introduced and evaluated in many large randomized trials showing a delay in tumor progression and an improvement in overall survival. This effective strategy should be taken into account when discussing the initial treatment plan and tailored according to the preferences of both patients and physicians.

Keywords: bevacizumab; docetaxel; erlotinib; gefitinib; lung cancer; maintenance; pemetrexed.

PubMed Disclaimer

References

    1. National Comprehensive Cancer Network. Non–small cell lung cancer (version 3.2014). (2014). Available: http://www.nccn.org/professionals/physician_gls/
    1. Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, et al. Phase III trial of two versus four additional cycles in patients who are non progressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 25(33):5233–910.1200/JCO.2007.10.8134 - DOI - PubMed
    1. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol (2009) 27:3277–8310.1200/JCO.2008.19.4522 - DOI - PubMed
    1. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 20:1335–4310.1200/JCO.20.5.1335 - DOI - PubMed
    1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355:2542–5010.1056/NEJMoa061884 - DOI - PubMed

LinkOut - more resources